Sanofi Acquires Rare Disease Developer Inhibrx for up to US$2.2 B
By Ashish Tripathi
Pharma Deals Review: Vol 2024 Issue 2 (Table of Contents)
Published: 22 Feb-2024
DOI: 10.3833/pdr.v2024.i2.2854 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to bolster its rare disease pipeline, Sanofi has agreed to acquire all the assets and liabilities associated with INBRX-101, for the treatment of patients with alpha-1 antitrypsin deficiency...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS